KM Research Hub
← 返回论文库
无 KM 图 入排:待复核 图源:可得 入排置信度 0.45

Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.

Nadine Norton, Nicholas B Larson, Gregory D Jenkins, Jan H Beumer, Brooke Langevin, Jogarao Gobbaru, Michael J Morris, Yusuke Nakamura, Deanna L Kroetz, Hao-Jie Zhu, Peter H O'Donnell, Lionel D Lewis, Daniel L Hertz

Clin Transl Sci 18(12) e70425

PMID41346252
PMCIDPMC12678863
DOI10.1111/cts.70425
发表日期2025-12-05
入排依据:The report describes a Phase III randomized trial (Alliance A031201) but is an analysis of genetic associations with drug clearance (pharmacokinetics). It does not report or focus on a primary/key secondary time-to-event efficacy endpoint such as OS or PFS. The study is therefore ineligible.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:非 KM 图;FIGURE 3:非 KM 图。
摘要

摘要

Enzalutamide and abiraterone are hormonal treatments that improve survival in metastatic castration-resistant prostate cancer. Identifying genetic variants associated with the clearance of these drugs may aid in improved dosing and outcomes. We performed genetic association studies of enzalutamide and abiraterone oral clearance in the Alliance A031201 clinical trial. Genome-wide genotyping was performed with the primary analysis limited to European-descent participants. Pharmacogene metabolic phenotypes were estimated using PyPGx and Stargazer. Associations of metabolic activity groups for CYP3A4, CYP3A5, CYP2C19 and SLCO1B1 with enzalutamide clearance (N = 706) and CYP3A4, SLCO2B1 and UGT1A4 with abiraterone clearance (N = 323) were tested by linear regression. Targeted SNP associations were assessed for abiraterone clearance at loci proximal to major metabolizing genes. Full genome-wide association studies were performed for both sets of clearance values. No significant associations were identified between metabolic phenotypes and enzalutamide or abiraterone oral clearance SNPs in the SULT2A1 5' flanking region were significantly associated with lower abiraterone clearance, (rs296373, minor allele frequency = 0.15, β = -0.457, p = 3.2E-06). Liver protein and liver and adrenal gland gene expression QTL databases indicated significantly lower SULT2A1 expression patterns for individuals carrying associated alleles, likely explaining the lower abiraterone oral clearance. CYP2C8*3 was associated with higher enzalutamide clearance (p = 0.012), but this was not significant after correction for multiple testing. This study is the first to identify the genetic association of SULT2A1, known to be involved in the metabolism of steroids in the liver and adrenal glands, with abiraterone clearance. Genetic variation in SULT2A1 may be useful to inform personalized dosing of abiraterone. ClinicalTrials.gov Identifier: NCT01949337.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1CONSORT diagram for the pharmacogenomic—pharmacokinetic study. Patients were included who identified as of European ancestry. AAP, abiraterone acetate plus prednisone; Enz, enzalutamide; PK, pharmacokinetic; QC, quality control.
非 KM Figure
FIGURE 2Single‐SNP associations with abiraterone clearance at the SULT2A1 locus, including (A) Locus Zoom plot at SULT2A1 and (B) SuSiE statistical fine‐mapping. PIP, posterior inclusion probability.
非 KM Figure
FIGURE 3(A) Manhattan plot of SULT2A1 PWAS. (B) Violin plot of SULT2A1 protein expression by rs296393. (C) Violin plot of abiraterone clearance by rs296393. PWAS, protein‐wide association study.
非 KM Figure